ClinicalTrials.gg
Active, not recruitingNCT05317728Updated Sep 1, 2026

Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design

An interventional study of BAL-FAIOL IOL and Monofocal IOL in Cataract, sponsored by Alcon Research. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Alcon Research (part of Alcon) · Not applicable, Interventional, and Device feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 116 studies in Cataract by Alcon — 4 open to participants now, 6 under way, none of them phase 3. Cataract · Alcon.

Enrollment
30th of 104
175 · median 95
Started
2023
with 3 others
No phase
66 of 116
2 open now
Registered
99th of 116
by date

Among the 116 studies in Cataract by Alcon, this one is the 30th largest by enrollment of the 104 interventional ones that give a count, is one of 4 that started in 2023, is one of 66 with no phase, and was the 99th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

4 of the 116 studies in Cataract by Alcon are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Cataract by Alcon, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the surgical, refractive, and visual outcomes with implantation of an investigational intraocular lens (IOL).

Read the detailed description

In this study, eligible subjects will receive cataract surgery with IOL implantation in both eyes. IOL implantation in the second eye is intended to occur between 7 and 15 days after IOL implantation in the first eye. Subjects will be followed for 1 year after implantation.

This study will enroll 2 cohorts. Cohort 1 subjects will be randomized to receive either the test IOL (BAL-FAIOL) or the control IOL (Monofocal). Cohort 2 subjects will receive the test IOL only (BAL-FAIOL). Cohort 2 will follow Cohort 1.

This study will be conducted in Central America.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • IOL
  • Intraocular lens
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to understand and sign an Institutional Review Board / International Ethics Committee approved form;
  • Willing and able to attend all scheduled study visits as required by the protocol;
  • Diagnosed with bilateral cataracts requiring removal by phacoemulsification with a clear corneal incision;
  • Other protocol-specified inclusion criteria may apply.

Key Exclusion Criteria:

  • Subjects taking medications that may affect accommodation;
  • eye abnormalities as specified in the protocol;
  • Previous eye surgery as specified in the protocol;
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Cohort 1: BAL-FAIOL

    BAL-FAIOL IOL implanted in both eyes during cataract surgery (bilateral implantation)

    Device: BAL-FAIOL IOL · Procedure: Cataract surgery

  • Active comparator
    Cohort 1: Monofocal

    Monofocal IOL implanted in both eyes during cataract surgery (bilateral implantation)

    Device: Monofocal IOL · Procedure: Cataract surgery

  • Experimental
    Cohort 2: BAL-FAIOL

    BAL-FAIOL IOL implanted in both eyes during cataract surgery (bilateral implantation)

    Device: BAL-FAIOL IOL · Procedure: Cataract surgery

Interventions

  • DeviceBAL-FAIOL IOL

    Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject

  • DeviceMonofocal IOL

    Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject

    Also known as: AcrySof IQ monofocal IOL (SN60WF)

  • ProcedureCataract surgery

    Phacoemulsification with a clear cornea incision

06

What researchers measure

Primary outcomes

  1. Mean Photopic Monocular Best Corrected Distance Visual Acuity (BCDVA) (4 meters)

    Distance visual acuity will be measured with correction in place for each eye individually using letter charts and recorded in logarithm Minimum Angle of Resolution (logMAR). This outcome measure is pre-specified for Cohort 1 and Cohort 2.

    Time frame: Month 6 post second eye implantation

  2. Cumulative Adverse Events, including Secondary Surgical Interventions (SSIs)

    The number of adverse events, including SSI's, will be calculated from time of implantation. This outcome measure is pre-specified for Cohort 1 BAL-FAIOL IOL only.

    Time frame: Up to Year 1

  3. Cumulative Adverse Events, including Secondary Surgical Interventions (SSIs) - Cohort 2

    The number of adverse events, including SSI's, will be calculated from time of implantation. The outcome measure is pre-specified for Cohort 2 only

    Time frame: Up to Year 1

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2026, 44 months after the start.

Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 44 months is above that.

Counting every sponsor, half of 493 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2022
First posted
Apr 8, 2022
StartActual
Mar 31, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05317728
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
Mar 31, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 1, 2026

Study contacts

Clinical Trial Lead, Surgical
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion